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Background: Recruiting regulatory CD4T cells (Tregs) into the tumor microenvironment
is an important tumor escape mechanism. Diminishing these suppressive cells is
therefore one of the targets of cancer immunotherapy. Selective depletion of Tregs has
proven successful in enhancing anti-tumor immunity and therapeutic efficacy in multiple
tumor types. However, the role of Tregs in oral/oropharyngeal cancers is unclear with
conflicting evidence regarding the effect of these suppressive cells on tumor prognosis.
In this study, we sought to review the role of Tregs in oral/oropharyngeal cancer with
the aim of deciphering the controversy regarding their effect on tumor progression and
prognosis.
Methods: A systematic review of the literature pertaining to the role of Tregs
in oral/oropharyngeal cancer was performed using Scopus, Embase, and PubMed.
Forty-five records were deemed eligible and data describing methodology of Treg
detection, tumor type, and association with prognosis were extracted.
Results: Of the 45 eligible manuscripts accepted for this systematic review, thirty-nine
studies reported data from human subjects while the remaining studies focused on
animal models. Sixteen studies were carried out using peripheral blood samples, while
samples from the tumor site were analyzed in 18 studies and 11 studies assessed
both blood and tumor samples. The transcriptional factor, Foxp3, was the most
commonly used marker for Treg identification (38/45). The findings of 25 studies
suggested that an increase in Tregs in the tumor microenvironment and/or peripheral
blood was associated with poorer prognosis. These conclusions were attributed
to the suppression of immune responses and the consequent tumor progression.
Conversely, nine studies showed an increase in Tregs in peripheral blood and/or tumor
microenvironment was related to a favorable prognosis, particularly in the presence of
human papilloma virus (HPV), the status of which was only assessed in 11 studies.
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Conclusions: This review underlines the importance of host immunity in the behavior of
oral/oropharyngeal cancer. Furthermore, we report an apparent lack of clarity regarding
the true role Tregs play in oral/oropharyngeal cancer progression which could be
attributed to inconsistent detection techniques of Tregs. Our results therefore highlight
the need for clearer methodologies and more robust phenotyping when defining Tregs.
Keywords: regulatory T cells, oral cancer, oropharyngeal cancer, patient outcome, tumor microenvironment
INTRODUCTION
Head and neck cancer is the sixth most common malignancy
with an estimated 686,000 new cases and 375,000 deaths
reported annually (combined worldwide laryngeal, oral, and
pharyngeal cancer incidence) (1). The majority of head and neck
cancers are squamous cell carcinoma (SCC). Along with alcohol
consumption, smoking and various forms of betel quid chewing
[which have long been associated with the development of oral
and oropharyngeal squamous cell carcinoma (OPSCC)], it is now
recognized that human papilloma virus (HPV) infection plays an
important role in the onset of HPV positive OPSCC (2).
Despite advances in diagnosis and treatment, OPSCC
mortality rate has improved little over the years, with 5 year
survival rates as low as 53% reported in England for cancers of the
oral cavity (3). This is mainly attributed to late diagnosis and the
absence of predictors of disease progression in oral premalignant
lesions.
Recently a growing emphasis is being placed on the role of
the immune system and its association with the occurrence and
progression of cancer. Indeed, cancer immunotherapy is among
the most important developments in cancer treatment. It was
therefore not surprising that cancer immunotherapy was named
the scientific breakthrough of the year in 2013 (4). Despite the
impressive successes in cancer immunotherapy, the response in
patients is sometimes short lived. This is due to factors that
hamper the immune response against cancer such as the presence
of the suppressive regulatory CD4T cells (Tregs) in the tumor
microenvironment (5).
Tregs are a subpopulation of CD4+ T lymphocytes which
are capable of discerning self-antigens from non-self-antigens
and suppressing the expansion of effector cells directed against
self. The major subpopulations of Tregs include thymus-derived
Tregs (tTregs), Tregs which have been induced peripherally
by different cytokines (pTregs), and induced Tregs which are
induced in vitro in the lab, (iTregs). All Treg types maintain
regulatory functions, and their development and function are
thought to be dependent on the expression of the transcription
factor Forkhead box P3 (FoxP3), known as the “master regulator”
of Treg regulatory functions (6, 7).
Within the tumor microenvironment, Tregs have an opposing
action to cytotoxic CD8T cells (8), and reducing the number
of Tregs was found to reinvigorate anti-tumor immunity and
promote tumor regression in different types of cancer (9–14).
The role of Tregs in oral/oropharyngeal cancer is not fully
understood and different studies have reported conflicting
evidence regarding the role of Tregs in oral/oropharyngeal
cancer progression and prognosis. Some studies emphasized the
suppressive role of Tregs within the tumor microenvironment
or the periphery, thus negatively impacting the patient clinical
outcome (15–20), others reported a positive clinical outcome
associated with an increase in circulating or tumor infiltrating
Treg (21–29).
It is therefore important to fully comprehend the causes
of these contradictions to enable full understanding of the
role that Tregs play in oral/oropharyngeal cancer. This will
enable designing novel immune-therapeutics that optimize the
anti-tumor immune response and ultimately clinical outcome.
In this study, we sought to review the role of Tregs in
oral/oropharyngeal cancer with the aim of deciphering the
controversy regarding their effect on tumor progression and
patient prognosis.
METHODS
We conducted and reported this systematic review following the
PRISMA statement (30).
Search Strategy
A systematic search of PubMed, Embase, and Scopus (from
their commencements to May 2017 when the search was
performed), for studies in the English language with no
species restrictions and for studies related to the role of
Tregs in oral and oropharyngeal cancer. The following
keywords were used in searching: (“head and neck cancer”
or “head and neck malignancy” or “oropharyngeal”) and
(“epithelial dysplasia” or “oropharyngeal premalignancy”) and
(“tumor microenvironment” or “cancer immunology” or “tumor
infiltrating lymphocytes” or “TILs” or “circulating immune cells”
or “peripheral immune cells”) and (“regulatory T cells” or
“regulatory T lymphocyte” or “regulatory CD4T lymphocyte” or
“regulatory CD4T cells” or “Treg” or “Tregs” or “Foxp3+ or
CD4+Foxp3+” or “CD25+” or “CD4+CD25+” or “suppressive
immune cells” or “suppressive lymphocytes”).
We scrutinized the reference lists of the identified reports,
reviews, meta-analyses, and other relevant publications to find
additional pertinent studies. The “related articles” function was
also used to broaden the search.
Our inclusion criteria were:
1- Studies must have been published as original articles
2- Studies must have been published in English
3- Studies assessing the role of Tregs in oral and oropharyngeal
cancer.
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Our exclusion criteria were:
1- Letters to the editor, conference abstracts, review, and systemic
review articles
2- Studies that focused on thyroid, laryngeal, esophageal, and
salivary gland tumors.
Data Extraction
The studies which met the inclusion criteria were summarized
and data extraction was performed using a pre-defined form by
one of the authors (CO) and accuracy checks were performed on
over 75% of the manuscripts by (RA). Data extracted included:
author, journal, year of publication, sample size, tumor type,
tumor site, species, whether blood or tumor sample were used,
method of sample analysis, markers used to detect Tregs, role of
Tregs in tumor progression/prognosis, HPV status, correlations
between HPV status and Tregs, tTregs vs. pTregs, and any data
related to oral epithelial dysplasia.
Due to the huge variation in the study designs, the number
of samples, the tumor site, and the method for detecting Tregs
within tumor or blood samples, meta analyses of the results were
not possible.
RESULTS
Manuscripts Included in the Systematic
Review
Of 715 identified citations, we identified 54 articles which
met the inclusion criteria. Following full text screening, 45
articles were deemed to be eligible for inclusion in this study.
Reasons for exclusion included irrelevant manuscripts which
did not tackle the role of Tregs in oral and oropharyngeal
cancer (n = 478), manuscripts that focused on tumors other
than oral or oropharyngeal; laryngeal/esophageal (n = 82),
salivary gland (n = 44), thyroid gland (n = 32) or gastric
tumors (n = 18), review articles (n = 13), one study looked
at the role of Tregs in periodontal disease and two articles
were excluded because they assessed the expression of Foxp3
in tumor cells rather than assessing Tregs. Figure 1 shows
the flow diagram of the studies retrieved for this systematic
review.
Data Summary
The full characteristics of the study populations are displayed in
Table 1.
Tumors
The majority of the studies [n = 39 (86.7%)] assessed human
samples (15–18, 20–29, 31, 33, 36–40, 42–51, 54–60), one study
assessed both human and murine samples (32), two studies
looked at murine samples (19, 34), one at rat (41), and two at
canine samples (52, 53). With the exception of two studies that
looked into multiple myeloma in canines (52, 53), all studies
focused on oral and/or oropharyngeal SCC [n = 43 (95.5%)].
Within the 45 studies, the site of the tumor varied and included
tumors of the oral cavity (tongue, floor of the mouth, base of
the tongue, gingiva), oropharynx, hypopharynx, lower lip, tonsil,
epipharynx, and lymph node metastasis. Three studies used head
and neck cancer cell lines (19, 40, 58).
Table 2 details the methodologies used to detect Tregs, the
markers used and the changes in Tregs observed with treatment
and with disease progression. Table 2 also summarizes the
suggested role of Tregs in oral and oropharyngeal cancer for each
included manuscript.
FIGURE 1 | Flow diagram of the studies retrieved for the review.
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TABLE 1 | Basic information about the 45 studies that met the inclusion criteria for this systematic review.
References Tumor
type
Tumor site Number of samples Sample Species
Stasikowska-
Kanicka et al.
(20)
SCC Oral cavity (floor of the mouth) 78 Patients (41 poor prognosis, 37 better prognosis)
18 Controls (normal mucosa)
Tumor Human
Hussaini et al. (31) SCC Oral cavity 25 Patients
12 Controls (inflammatory hyperplastic tissue)
Tumor Human
Ihara et al. (17) SCC Oral cavity, oropharynx,
nasopharynx, larynx, maxillary
sinus
46 SCC
23 Controls
Blood Human
Ma et al. (32) SCC HNC Human samples:
43 Normal
48 Dysplastic
165 Primary HNSCC
12 Recurrent HNSCC
17 HNSCC with induction chemotherapy
Murine samples:
6 WT normal tongue
6 WT tumor bearing mice
6 KO tumor bearing mice
Tumor Human/Murine
Zhou et al. (33) SCC Tongue 46 SCC
46 Paired tumor adjacent non-neoplastic tongue epithelium
20 Metastasis lymph nodes
20 Paired normal cervical lymph nodes
Tumor Human
Nguyen et al. (25) SCC Larynx, oral cavity, oropharynx,
hypopharynx
278 SCC Tumor Human
Miki et al. (34) SCC Tongue 20 Controls
20 4NQO
40 4NQO treated with COX-2 inhibitor
Tumor Murine
da Cunha Filho
et al. (35)
SCC Low lip 50 Patients, 10 microscopic fields per patient Tumor Human
Montler et al. (36) SCC Base of the tongue, tonsil,
oropharynx, nasal, oral tongue,
mandibular gingiva, maxillary
sinus, larynx, floor of the mouth
29 Patients Tumor
blood
Human
Takahashi et al.
(37)
SCC Oral cavity, oropharynx,
hypopharynx, larynx, paranasal
cavity
20 Healthy controls
44 Patients treated with surgery/radio/radio-chemotherapy
16 Chemotherapy
Blood Human
Jie et al. (18) SCC Oral cavity, oropharynx, larynx,
hypopharynx
22 Patients treated with cetuximab plus
cisplatin/paclitaxel/radiotherapy followed by 6 months of
maintenance single agent cetuximab
18 Patients received single-agent cetuximab
Tumor
blood
Human
Partlova et al. (38) SCC Tongue, tonsil, larynx, verbal
base, hypopharynx, Gl.
submandibularis, floor of mouth
54 Patients Tumor
blood
Human
Wolf et al. (29) SCC Oral cavity: tongue, upper
alveolus, floor of mouth, hard
palate, buccal mucosa, and
retromolar
39 Patients Blood Human
Sun et al. (39) SCC Oral cavity, hypopharynx,
nasopharynx, oropharynx, larynx
112 Patients
31 Healthy donors
Blood Human
Schipmann et al.
(40)
SCC Oral cavity and skin FOXP3 mRNA expression:
13 Cutaneous cSCC
8 Oral SCC
14 SCC metastases
Immunohistochemistry:
10 Cutaneous SCC
8 Oral SCC
4 SCC metastases
10 Normal skin control
Cell lines:
Primary human adult skin fibroblasts
Human squamous cell carcinoma cell line
Tumor Human
(Continued)
Frontiers in Oncology | www.frontiersin.org 4 October 2018 | Volume 8 | Article 442
O’Higgins et al. Tregs in Oral and Oropharyngeal Cancer
TABLE 1 | Continued
References Tumor
type
Tumor site Number of samples Sample Species
Lim et al. (23) SCC Oral cavity 39 Patients
24 Controls
Blood Human
Hanakawa et al.
(16)
SCC Tongue 34 Patients Tumor Human
Ward et al. (28) SCC Oropharynx 149 HPV+
121 HPV–
Tumor Human
Lukesova et al.
(24)
SCC Oral cavity, oropharynx 60 Patients Blood Human
Zhao et al. (41) SCC Tongue 16 Controls
32 4NQO
Tumor
blood
Rat
Jie et al. (42) SCC Oral cavity, oropharynx 27 Patients Tumor
blood
Human
Park et al. (26) SCC Tonsil 79 Patients Tumor Human
Weed et al. (43) SCC Tongue 49 Patients Tumor Human
Drennan et al. (44) SCC Oropharynx, larynx 14 Controls
39 Patients
Blood Human
Bron et al. (22) SCC Oral cavity, oropharynx,
hypopharynx, larynx
35 Patients Tumor
blood
Human
Judd et al. (19) SCC Oral cancer cell line injected in
flank
Not disclosed in manuscript Tumor Murine
Gaur et al. (45) SCC Oral cavity 45 Patients
40 Controls
Blood Human
Wansom et al. (27) SCC Oropharynx 46 Patients Tumor
blood
Human
Wild et al. (46) SCC Oral cavity, pharynx, larynx 35 Patients
17 Controls
Tumor
blood
Human
Näsman et al. (47) SCC Tonsil 31 HPV+ with a good clinical outcome
21 HPV+ with a poor clinical outcome
11 HPV– with a good clinical outcome
20 HPV– with a poor clinical outcome
Tumor Human
Lee et al. (48) SCC Oral cavity 38 Patients
5 Controls
Tumor
blood
Human
Schuler et al. (49) SSC Oral cavity, pharynx, larynx 9 Patient samples for dendritic cell culture
13 Patient samples for Treg frequency
Blood Human
Alhamarneh et al.
(50)
SCC Larynx, oropharynx, oral cavity,
hypopharynx, nasal cavity, lymph
node metastasis, unknown
primary site
107 Patients pretreatment
43 4–6 weeks posttreatment
40 Controls
Blood Human
Al-Qahtani et al.
(51)
SCC Oral cavity 34 Patients Tumor Human
Tominaga et al.
(52)
MM Oral cavity 7 Patients
10 Controls
Tumor
Blood
Canine
Horiuchi et al. (53) MM Oral cavity 15 Patients
10 Controls
Blood Canine
Schott et al. (54) SCC Epipharynx, oropharynx,
hypopharynx, larynx, oral cavity
16 Patients with active disease
16 Patients with no evidence of disease
21 Controls
Blood Human
Gasparoto et al.
(55)
SCC Oral cavity, lip 9 Patients
10 Controls
Tumor
Blood
Human
Boucek et al. (15) SCC Oral cavity, hypopharynx, larynx 112 Patients
20 Controls
Blood Human
Distel et al. (56) SCC Oral cavity, hypopharynx,
oropharynx
62 Low-risk group patients with early disease
53 High-risk group inoperable patients with advanced disease
Tumor Human
Schwarz et al. (57) SCC Oral cavity 15 Patients
15 Controls
Tumor Human
(Continued)
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TABLE 1 | Continued
References Tumor
type
Tumor site Number of samples Sample Species
Bergmann et al.
(58)
SCC HNSCC cell lines from primary
tumors
Cell culture of irradiated HNSCC cell lines from primary
tumors with blood samples from 10 healthy donors
Blood Human
Chikamatsu et al.
(59)
SCC Oral cavity, oropharynx,
hypopharynx, larynx, paranasal
sinuses
43 Patients
24 Controls
Blood Human
Badoual et al. (21) SCC Oral cavity, oropharynx,
hypopharynx
84 Patients Tumor Human
Schaefer et al. (60) SCC Larynx, oral cavity, pharynx,
hypopharynx
24 Patients
17 Controls
Blood Human
SCC, Squamous Cell Carcinoma; MM, Multiple Myeloma; HNC, Head and Neck Cancer; HNSCC, Head and Neck Squamous Cell Carcinoma.
Samples and Treg Analyses
Eighteen studies assessed tumor samples (16, 19–21, 25, 26,
28, 31–35, 40, 43, 47, 51, 56, 57), 16 assessed blood samples
(15, 17, 23, 24, 29, 37, 39, 44, 45, 49, 50, 53, 54, 58–60), and 11
studies assessed both tumor and blood samples (18, 22, 27, 36,
38, 41, 42, 46, 48, 52, 55).
With regards to the methodologies used to detect and assess
Tregs, immunohistochemistry was used in 21 studies (16, 20, 22,
24–29, 31–36, 40, 47, 48, 51, 56, 57), flow cytometry in 25 studies
(15, 17–19, 23, 24, 32, 36–39, 41, 42, 44–46, 48–50, 52–55, 58–
60), Immunofluorescence in six studies (21, 31, 32, 43, 46, 52),
PCR in six studies (24, 34, 38, 40, 46, 48), ELISA in four studies
(23, 46, 50, 58), Histopathology and morphology in three studies
(20, 34, 35), and Western blots in two studies (32, 58). The
majority of the studies (30 out of 45 studies) used only a single
method for detecting Tregs (15–19, 21, 22, 25–29, 33, 37, 39, 41–
45, 47, 49, 51, 53–57, 59, 60). The most common single method
was flow cytometry (16 out of 30) (15, 17–19, 37, 39, 41, 42, 44,
45, 49, 53–55, 59, 60), followed by immunohistochemistry (12 out
of 30) (16, 22, 25–29, 33, 47, 51, 56, 57) and immunofluorescence
was used as a single method for Treg detection in two studies
(21, 43). Eight out of the 45 studies used two methods of
Treg assessment (20, 23, 31, 35, 36, 40, 50, 52) while seven
studies used three or more methodologies (24, 32, 34, 38, 46, 48,
58).
As for the markers used to detect Tregs and assess their
function, Foxp3 was the most commonly used marker, as it was
used in 38 out of the 45 studies (16–22, 25–29, 31–36, 39–43, 45–
58, 60). Foxp3 was the sole marker for Treg detection in 13
studies (16, 20, 22, 25, 27–29, 34, 35, 40, 47, 51, 56). Foxp3 in
combination with T cell markers CD3, CD4, and/or CD25, was
used as a marker in 14 studies (15, 19, 24, 26, 33, 41, 43, 45,
49, 52, 53, 57, 59). CD25 was used as a marker (on its own or
with other markers) in 24 studies (15, 18, 21, 23, 24, 26, 36–
39, 41, 42, 44–46, 48–50, 54, 55, 58–60). Seven studies identified
Tregs using a combination of CD4+CD25+CD127low with or
without other markers (17, 23, 37, 38, 44, 46, 54). CTLA-4 was
used as a marker of Treg phenotype or suppressive function in
seven studies (18, 36, 42, 50, 54, 55, 58), GITR was assessed in
four studies and as a marker of Treg function (50, 54, 55, 60),
TGF-β was assessed in four studies (18, 42, 48, 55), and IL-10 was
used in two studies (55, 58).
HPV Status
Only 11 manuscripts looked at the HPV status of the tumors
(24–29, 32, 36, 38, 43, 47), and out of those, only 10 included
HPV positive cases in their studies (24–29, 32, 36, 38, 47).
Half these studies reported no difference in Treg levels between
HPV positive and negative tumors (24, 27, 29, 32, 36). Two
manuscripts reported a decrease in Treg proportion in HPV
positive (28, 38) [one associated with an increase in TIL (28)],
and three reported an increase in Treg associated with an overall
increase in TIL (24, 25, 47). Four studies associated HPV positive
tumors with better survival compared to HPV negative (24, 27,
28, 47). One study found no correlation between HPV status and
survival (29). Three studies correlated an increase in Tregs in
HPV positive tumors with better prognosis (24, 26, 28), however,
one of the studies suggested that it was associated with the overall
increase in TIL (28).
Correlation of Tregs With Clinical Outcome
Twenty-four studies reported a clear increase in Tregs (whether
intratumoral or circulating) in cancer patients in comparison to
healthy controls and/or in more advanced disease (15, 20, 23, 31–
34, 37, 39–41, 44, 45, 48–55, 57, 59, 60). Only three studies
reported a decrease in Tregs with more advanced disease (22, 29,
35).
Out of the 45 papers included in this study, 25 studies (55.6%)
found a correlation between Tregs and poor clinical outcome
and disease progression (15–20, 32, 33, 37, 39–42, 44–46, 48,
49, 51–55, 58, 59), nine manuscripts (20%) correlated Tregs to
good clinical outcome (21–29), and 11 (24.4%) did not reach
a conclusion regarding the role of Tregs in tumor progression
(31, 34–36, 38, 43, 47, 50, 56, 57, 60).
No apparent correlation was found between the site of
the tumor and the outcome. Only one study reported higher
numbers of Tregs in Oral SCC lesions in comparison to
oropharyngeal tumors (24).
With regards to the type of samples assessed for Tregs,
interestingly, the majority of the studies that could not conclude
the role of Tregs [7 out of 11 studies (63.6%)] looked only
at tumor samples (31, 34, 35, 43, 47, 56, 57). Four of the
studies that only assessed tumor samples showed an association
between Tregs and good prognosis (21, 25, 26, 28), while
seven showed association with poor prognosis and clinical
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progression (16, 19, 20, 32, 33, 40, 51). Regarding the studies that
assessed blood samples only, the majority [11 out of 16 (68.7%)]
reported an association between Tregs and poor outcome (15,
17, 37, 39, 44, 45, 49, 53, 54, 58, 59), while three studies
reported a good outcome (23, 24, 29) and two studies could
not conclude a definite role (50, 60). When both tumor and
blood samples were assessed, only two studies (out of 11) could
not define a role for Tregs in disease progression (36, 38), two
studies found a positive correlation with good outcome (22, 27)
while the remaining seven studies reported a correlation with
poor outcome and disease progression (18, 41, 42, 46, 48, 52,
55).
Regarding the method used to detect Tregs, interestingly,
flow cytometry was only used in two of the nine studies that
concluded a good prognosis (23, 24), and four out of the studies
that made no conclusion (36, 38, 50, 60). On the other hand,
immunohistochemistry was used in seven out of the nine studies
that found a positive connection between Treg and a better
clinical outcome (22, 24–29), and seven out of the studies that
made no conclusion (31, 34–36, 47, 56, 57).
As for the markers used, remarkably, Foxp3 was the only
marker used to identify Tregs in five out of the nine studies
that suggested a positive clinical outcome with an increase of
Tregs (22, 25, 27–29). Five out of the seven studies that used
CTLA-4 as a marker of Treg correlated the presence of Treg
with a poor clinical outcome (18, 42, 54, 55, 58). The remaining
two did not conclude a definitive role for Tregs (36, 50). On
the other hand, out of the four studies that assessed GITR,
two associated Tregs with poor clinical outcome and disease
progression (54, 55), while the other two did not conclude a role
(50, 60). All four studies that assessed TGF-β as a marker of Treg
function found a negative clinical outcome associated with Treg
(18, 42, 48, 55).
DISCUSSION
Cancer immunotherapy to reactivate anti-tumor immunity is one
of the most important recent developments in cancer treatment.
For some patients, targeting the immune system to boost its
anti-tumor activity can generate enduring disease remission, but
despite the impressive successes in cancer immunotherapy, the
response in patients is sometimes transient. This is attributed
to multiple factors including the exhaustion of tumor-specific
CD8T cells in addition to induced suppression of the immune
response against cancer. One of the major immune escape
mechanisms in cancer patients is the conversion and dominance
of suppressive immune cells within the tumormicroenvironment
that hamper the function of anti-tumor effector T cells.
Regulatory CD4T cells (Tregs) are among the most studied
suppressor cells in the tumor microenvironment and their role in
mediating tumor progression has been reported in many types of
cancer. Indeed, reducing the number of Tregs has been reported
to enhance anti-tumor immunity and promote tumor regression
(9–14).
However, in head and neck cancer and particularly in OPSCC,
the role of Tregs in mediating tumor progression and affecting
the overall clinical outcome is not clear. In fact, there are
conflicting reports in the literature; while a considerable number
of studies reported a similar role for Tregs in mediating tumor
escape mechanisms and facilitating tumor progression (15–20),
other studies reported an opposite role and associated Tregs with
a positive clinical outcome (21–29).
In this systematic review, we attempted to assess the body of
knowledge available about the role that Tregs play in head and
neck cancer with the aim of understanding the reasons for this
contradiction in describing the role that Tregs play in disease
progression and the clinical outcome.
Our findings emphasized the controversy in the literature. An
elevated level of Tregs in patients was observed in some studies
(15, 20, 23, 31–34, 37, 39–41, 44, 45, 48–55, 57, 59, 60), while
no significant differences were reported between patients and
healthy controls in others and a decrease in Tregs with more
advanced disease was observed in three studies (22, 29, 35).While
more than half of the reviewed studies reported a poor prognosis
associated with increased levels of Tregs (15–20, 32, 33, 37, 39–
42, 44–46, 48, 49, 51–55, 58, 59), many studies reported a
better prognosis (21–29). A considerable number of studies did
not conclude a role for Tregs in tumor progression or clinical
outcome (31, 34–36, 38, 43, 47, 50, 56, 57, 60).
One of the potential reasons for the controversy in the
literature, is different reports from different species. We therefore
included all the manuscripts from all species to assess whether
the species under study affected the reported outcome. The only
study that assessed both human and murine samples reported
a role for Tregs in promoting tumor progression (32). One of
the two studies that assessed murine sample did not reach a
conclusion about the role of Tregs (34), while the second murine
study reported a role for Tregs in enhancing tumor progression
(19). Similar results about the role of Tregs in promoting disease
progression were reported in the only study that assessed rat
samples (41) and the two canine samples (52, 53). These findings
ruled out any role for inter-species variability in the controversy
in the literature.
In recent years, the incidence of HPV positive oropharyngeal
cancers has increased and is on the rise. Surprisingly, we report
that HPV status was assessed in only 11 studies out of the
45 included in this systematic review. HPV-associated tumors
are a distinct subtype with different intra-tumoral immune cell
infiltration and better prognosis (24, 27, 28, 47). Therefore,
phenotyping tumors according to their HPV positivity is essential
when assessing the role of different immune cells in anti-tumor
immunity.
Despite the advances in head and neck cancer diagnosis and
treatment, the mortality rate is still high. This is mainly attributed
to late diagnosis and the lack of predictors of disease progression.
Premalignant lesions are altered tissues that carry a higher
risk of developing into malignancy, but unfortunately markers
to predict malignant transformation into malignancy in these
lesions are lacking. Surprisingly, among all the reviewed articles
in this study, only three studies assessed premalignant lesions in
animal models (32, 34, 41), and only one of these studies assessed
samples from human patients (32). All three studies reported
an increase in suppressive Tregs with disease progression from
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normal through dysplastic to neoplastic lesions (32, 34, 41). In
their study, Ma et al. reported a correlation between disease stage
and Tregs and in particular in A2AR expression. They reported
that blocking A2AR reduced Tregs in the tumor bearing mice
and enhanced anti-tumor immune response (32). Understanding
the immune response within premalignant lesions is crucial
to predict their progression into malignancy and to design
treatments to modulate the immune response to eliminate these
lesions before transforming into cancerous lesions.
Interestingly, distinction between thymic vs. peripheral
Treg within the tumor microenvironment was not made nor
assessed in any of the identified manuscripts in this systematic
review. This is not a surprise given the lack of markers that
accurately determine the origin of Tregs, but certainly measuring
intratumoral numbers of converted Treg, defined by markers
such as CD103 or S1PR may yield more precision for the role
that Treg play within the tumor microenvironment.
In this systematic review, we found that Foxp3 is the most
commonly used marker for Treg identification. In fact, it was
the only marker used in 13 studies (16, 20, 22, 25, 27–29, 34, 35,
40, 47, 51, 56). Many of the studies used immunohistochemistry
and a single stain to detect Foxp3. This causes a potential
problem as Foxp3 is highly expressed in other activated T
cell subsets including effector T cells. In fact, it has been
proposed that under certain inflammatory condition, Foxp3+
Tregs might become unstable adopting a phenotype that is more
characteristic of effector CD4+ T cells (61). Foxp3 might be a
marker of activation rather than a marker of regulation and a
key identifier of Tregs. Therefore, using dual staining and co-
localization of markers such as CD4 and Foxp3 could clarify the
role of Treg TIL subset in the tumor microenvironment more
accurately.
Furthermore, Foxp3 is expressed in tumor cells. In fact, it has
been reported that tongue SCC tumor cells express Foxp3 and
its expression significantly associated with disease progression
and poor patient outcome (62). The same group found that
Foxp3 expressed in tumor cells has distinct biological functions
compared with that in Tregs (63). On the other hand, the
expression of Foxp3 in tumor cells is associated with an increase
in the secretion of sCTLA-4, which was recently reported to be
a favorable predictor of clinical outcome in advanced cancers
(64). This could explain the reported association between Tregs,
as identified by Foxp3 expression, and a favorable clinical
outcome.
This adds to the controversy regarding the role of Tregs and
emphasizes the need to use more than one method and different
markers to detect Tregs within the tumor microenvironment.
Remarkably, immunohistochemistry was the only used method
to assess Tregs in 21 studies (16, 20, 22, 24–29, 31–36, 40,
47, 48, 51, 56, 57). A study further suggests that the overall
expression of Foxp3 in Tregs by itself is not an important
predictor of clinical outcome, but rather the localization of
Foxp3 is the important predictor of outcome. Weed et al.
reported that in oral SCC, nuclear Foxp3 is associated with a
higher probability of early disease recurrence in comparison to
cytoplasmic Foxp3, which is associated with a lower probability
of recurrence (43). Immune profiling and the pattern of TIL
within the tumors is of great importance as reported by Feng
et al. after we conducted our search. They reported that the
distance between the suppressive Foxp3+ Tregs and the effector
CD8+ T cells are predictive of patient overall survival (65).
Surprisingly, despite the great advances in different assays that
added to the confidence in defining Treg markers, our study
did not find any major changes in the assays or markers
used to detect Tregs over the 12 year period (2005-2017)
that the manuscripts included in this review covered. These
reports emphasize the importance of using different markers,
assays and analyses in the study of immune cells in cancer
patients.
Checkpoint inhibitor antibodies represent a novel type of
cancer immunotherapy that has seen notable success in the
treatment of different cancers (66). One of the major targets
of checkpoint inhibitors is CTLA-4, which is highly expressed
on Tregs. Only seven studies out of the 45 studies that we
assessed looked at the expression of CTLA-4 in Treg or used
it as an identifier for these suppressor cells (18, 36, 42, 50, 54,
55, 58), five of which correlated the presence of Treg with a
poor clinical outcome (18, 42, 54, 55, 58). One of these studies
reported a higher frequency of CTLA-4+ Tregs (identified as
CD4+CD25hiFoxp3+) in non-responder patients to Cetuximab
(18), suggesting a potential use of this immune checkpoint as a
biomarker for response to therapy.
GITR, another immune checkpoint was assessed in four
studies as a marker of Treg function (50, 54, 55, 60), two of
which associated Tregs with poor clinical outcome and disease
progression (54, 55). TGF-β was assessed in four studies as by the
membrane bound form (LAP), or using RT-PCR (18, 42, 48, 55),
all of which correlated Tregs to poor clinical outcome.
CONCLUSIONS
In conclusion, our systematic review emphasized the existing
controversy regarding the role of Tregs in head and neck cancer,
and in particular in OPSCC. We conclude that similar to most
cancer types, Tregs contribute to tumor escape mechanisms
and are therefore associated with poor clinical outcome. The
inconsistent results reported in the literature could be due to the
use of different markers to identify Tregs, variation in patient
recruitment criteria or a heterogeneous cancer population.
Indeed, we observed major differences in the reported outcomes
between studies that assessed tumor samples, and those that
assessed blood samples, suggesting the need to assess both to
reach a more definitive understanding of the role of different
immune cells in disease progression. HPV status, an important
prognostic marker in OPSCC, was not assessed in majority of
the studies, which could explain some of the discrepancy in the
findings.
Our findings therefore suggest the need to define a better
and more robust method to detect Tregs in the tumor
microenvironment and in the periphery using a combination
of methodologies, markers and analyses. We suggest using
a combination of markers to define Tregs in the periphery
and within TIL, including CD4, CD3, CD25, CD127lo, FoxP3,
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and CTLA-4. We also propose incorporating the regulatory
properties of tumor cells as well as TIL for a complete picture
of the tumor microenvironment.
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